2024
A New Chimeric Antibody against the HIV-1 Fusion Inhibitory Peptide MT-C34 with a High Affinity and Fc-Mediated Cellular Cytotoxicity
Kalinichenko S, Ramadan L, Kruglova N, Balagurov K, Lukashina M, Mazurov D, Shepelev M. A New Chimeric Antibody against the HIV-1 Fusion Inhibitory Peptide MT-C34 with a High Affinity and Fc-Mediated Cellular Cytotoxicity. Biology 2024, 13: 675. PMID: 39336102, PMCID: PMC11428423, DOI: 10.3390/biology13090675.Peer-Reviewed Original ResearchCellular cytotoxicityHIV-1Chimeric antibodyInhibitors of HIV-1 entryAntibody-dependent cellular cytotoxicityHIV-1 infectionHIV-1 entryRecombinant chimeric antibodyHumanized antibody trastuzumabMouse monoclonal antibodyCXCR4 locusCD4 lymphocytesCD4 cellsParental mouse monoclonal antibodyCAR cellsGeneration of antibodiesAntibody trastuzumabMonoclonal antibodiesAntibodiesMouse hybridomasConstant regionKnock-inCellsCytotoxicityPeptide
2023
Ultrasensitive quantification of HIV-1 cell-to-cell transmission in primary human CD4+ T cells measures viral sensitivity to broadly neutralizing antibodies
Mazurov D, Herschhorn A. Ultrasensitive quantification of HIV-1 cell-to-cell transmission in primary human CD4+ T cells measures viral sensitivity to broadly neutralizing antibodies. MBio 2023, 15: e02428-23. PMID: 38063394, PMCID: PMC10790777, DOI: 10.1128/mbio.02428-23.Peer-Reviewed Original ResearchConceptsHIV-1 cell-to-cell transmissionCell-to-cell transmissionHIV-1Neutralizing antibodiesHIV-1 escapeHIV-1 transmissionHIV-1 resistanceHuman T cellsT cellsClinical trialsMode of transmissionViral sensitivityUltrasensitive assayEvaluation of pre-existingAntibodiesAssayCellsPre-existingRetrovirusesTrials
2022
An ELISA Platform for the Quantitative Analysis of SARS-CoV-2 RBD-neutralizing Antibodies As an Alternative to Monitoring of the Virus-Neutralizing Activity
Kostin N, Bobik T, Skryabin G, Simonova M, Knorre V, Abrikosova V, Mokrushina Y, Smirnov I, Aleshenko N, Kruglova N, Mazurov D, Nikitin A, Gabibov A. An ELISA Platform for the Quantitative Analysis of SARS-CoV-2 RBD-neutralizing Antibodies As an Alternative to Monitoring of the Virus-Neutralizing Activity. Acta Naturae 2022, 14: 109-119. PMID: 36348715, PMCID: PMC9611858, DOI: 10.32607/actanaturae.11776.Peer-Reviewed Original ResearchVirus-neutralizing activitySARS-CoV-2Levels of SARS-CoV-2 neutralizing antibodiesSARS-CoV-2 neutralizing antibodiesNeutralizing activity of seraGroup of hospitalized patientsSARS-CoV-2 vaccinesImmunity to SARS-CoV-2Gam-COVID-Vac vaccineActivity of seraHumoral immune responseSARS-CoV-2 infectionGam-COVID-VacNeutralizing antibodiesImmune plasmaSerum immunoglobulinsHospitalized patientsImmune responseELISA platformVirus assayProtective effectAntibodiesHerd immunity to SARS-CoV-2VaccineVirus variants
2014
Epitope mapping of lymphocyte phosphatase-associated phosphoprotein
Filatov A, Meshkova T, Mazurov D. Epitope mapping of lymphocyte phosphatase-associated phosphoprotein. Biochemistry (Moscow) 2014, 79: 1397-1404. PMID: 25716735, DOI: 10.1134/s0006297914120153.Peer-Reviewed Original ResearchConceptsLymphocyte phosphatase-associated phosphoproteinAmino acid sequenceAcid sequencePoint mutantsAntigenic stimulation of lymphocytesTransmembrane proteinsPhosphatase CD45Stimulation of lymphocytesReaction of antibodiesAntigenic epitopesAntigenic stimulationProteinCell activationMonoclonal antibodiesEpitopesAntibodiesMutantsLymphocytesPhosphoproteinPhosphorylation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply